A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 4 more changesShow less
    • Enrollment target: estimated 60 to confirmed 61
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints: details revised at 4 of 10 entries
    • Site details revised at 2 of 2 sites
  2. Eligibility criteria expanded, about 4 wordsv5
  3. Recruitment opened
    • Start date changed from estimate of Apr 2026 to Apr 23, 2026
    • Site details revised at 2 of 2 sites
    v4
  4. Start date: Mar 2026 to Apr 2026v3
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a multicenter, randomized, double-blind, placebo-parallel-controlled phase II clinical trial to evaluate the efficacy and safety of HRS-1780 compared with placebo in participants with primary aldosteronism. The study plans to enroll 60 participants.
Trial Details
NCT Number NCT07470983
Lead Sponsor Shandong Suncadia Medicine Co., Ltd.
Conditions
(from sponsor)		 Primary Aldosteronism
Related terms Hyperaldosteronism
Enrollment 61 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov